Congress Gave Physicians a 2.5% Raise. Medicare's Fine Print Took It Back — Here's the Efficiency Adjustment Math That's Destroying Oncology, Ophthalmology, and OB/GYN

The 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F), finalized October 31, 2025, contains a regulatory structure that most practice administrators have not yet decoded. Congress mandated a 2.5% physician payment increase in H.R. 1. CMS enacted it in the conversion factor, then applied a -2.5% efficiency adjustment to work relative value units across more than 7,000 non-time-based service codes, covering 95% of all physician services. The raise and the reduction are, by design, equivalent in magnitude. For procedure-heavy specialties, the net result is a structural reimbursement contraction that will repeat every three years unless Congress intervenes.

The Accounting Trick Inside the 2026 Fee Schedule: How a 2.5% Raise Became a Net Zero (or Worse)

The efficiency adjustment mechanism draws from the five-year cumulative productivity adjustment embedded in the Medicare Economic Index. CMS's calculation produced a -2.5% factor, which it applied directly to work RVUs and corresponding intraservice physician time for all non-time-based services. The conversion factor nominally increased to $33.40 for non-qualifying APM participants and $33.57 for qualifying APM participants, which looks like progress until you realize those gains dissolve at the wRVU level for any code outside the exempt categories.

The logic CMS used to justify this is worth understanding because it reveals the agency's long-term posture: physicians become more efficient as they perform procedures repeatedly, so the work input for a given procedure should decline over time. That assumption has no grounding in clinical evidence for complex procedures like allogeneic transplantation or retinal surgery. The American Medical Association stated plainly that the adjustment reduces payment for more than 7,000 services and that CMS intends to revisit it every three years with no floor on how deeply a service can be devalued. That triennial reset is the mechanism that turns a one-time policy into a permanent devaluation trajectory.

Practice managers who modeled 2026 budgets on the headline +2.5% statutory increase have already absorbed the error. The question now is how to respond before the next cycle compounds it.

Which Specialties Get Hit Hardest and Why: Oncology, Ophthalmology, and OB/GYN in the Crosshairs

Oncology is the most severe case. The AMA's analysis found that 37% of oncologists face net cuts of 10 to 20%, a figure that reflects both the efficiency adjustment and a second simultaneous policy change: CMS reduced indirect practice expense RVUs for facility-based services, allocating facility PE at half the rate of non-facility settings. Facility-based hematology/oncology practices face an approximately 11% payment decrease while community-based oncology practices see a roughly 6% increase. A hospital-employed oncologist is absorbing both the wRVU reduction and the facility PE cut on the same claim.

ASCO documented the CPT-level impact: CPT 38240 (allogeneic hematopoietic progenitor cell transplantation) had its work RVU reduced from 4.00 to 3.90, with intraservice time cut from 120 to 118.5 minutes. CPT 38241 (autologous HPC transplantation) dropped from 3.00 to 2.93 wRVUs. Drug administration codes, which anchor community oncology revenue, received a one-year exemption for 2026 following ASCO advocacy, but that exemption expires January 1, 2027. Oncology practices treating that exemption as a resolved issue are planning for a cliff they haven't yet cleared.

Ophthalmology faces a structurally similar problem. CMS analysis found that 54% of ophthalmologists face net payment cuts, because cataract surgery, retinal procedures, glaucoma interventions, and diagnostic imaging all sit in the non-time-based category. The efficiency adjustment hits the core of the specialty's revenue mix, not its margins.

OB/GYN has a more complex exposure profile. Maternity codes with an MMM global period are exempt from the efficiency adjustment, but gynecologic surgical procedures, diagnostic hysteroscopy, colposcopy, and office-based procedural codes carry non-time-based classifications. The AMA found that 37% of OB/GYNs face net cuts under the combined policies, reflecting how much of a typical mixed OB/GYN practice's revenue comes from procedural rather than maternity billing.

Reading the Fine Print: What 'Non-Time-Based Services' Actually Means for Your CPT Mix

The exempt category deserves precise definition because practices commonly overestimate how much of their billing it covers. Time-based services include evaluation and management codes, care management codes, behavioral health services, telehealth services listed on the Medicare telehealth list, and maternity codes with global period MMM. These are exempt because their valuation depends on documented physician time, which CMS cannot claim has become more efficient without contradicting its own documentation requirements.

Every procedural CPT code that lacks a direct physician-time component is non-time-based. This includes the vast majority of surgical, diagnostic imaging, infusion, and minor procedure codes billed across specialty medicine. Practice administrators should run a CPT-level revenue audit sorted by gross revenue contribution and non-time-based classification status. Any code generating more than 5% of a specialty practice's gross revenue in the non-time-based column represents compounding exposure: current cuts in 2026, next reset in 2029 at minimum, with no statutory protection against further devaluation.

For mixed-service practices, the audit also surfaces an opportunity. Shifting volume toward time-based billing where clinically appropriate through expanded care management, chronic condition monitoring, and behavioral health integration adds exempt revenue and may generate quality performance credit in MIPS and APM contexts simultaneously.

The AMA's Pushback: Legal Challenges, Congressional Asks, and Why the Timeline Matters for Your Planning

The AMA has opposed the efficiency adjustment since the proposed rule was published in July 2025. Its advocacy operates on two tracks. The legislative track supports H.R. 6160, the Strengthening Medicare for Patients and Providers Act, which would establish permanent annual MEI-based updates, and H.R. 8163, the Provider Reimbursement Stability Act, introduced on bipartisan basis March 30, 2026. Bipartisan House members introduced additional legislation in April 2026 specifically targeting budget-neutrality constraints in the fee schedule.

The data-collection track is building an administrative record for future rulemaking challenges, following the same playbook that eventually produced the repeal of the Sustainable Growth Rate formula in 2015 after a decade of congressional patches. The SGR repeal took fifteen years and annual emergency fixes. Practices that are waiting for legislative relief before adjusting their financial models are accepting a multi-year exposure they could begin mitigating now.

The more significant near-term risk is the drug administration code exemption for oncology. ASCO secured a one-year carve-out for 2026. The advocacy campaign to extend it into 2027 is ongoing, but there is no guarantee of success, and oncology practices that have not modeled their 2027 revenue without the exemption are underestimating their downside.

Contract Renegotiation, Service Mix Shifts, and Facility Decisions: A Three-Option Response Framework

Three levers are available to practices facing material revenue erosion, and the window to act on at least two of them is closing.

Payer contract renegotiation is the most immediate lever. Commercial contracts that peg reimbursement to Medicare allowables or Medicare fee schedule percentages will automatically propagate the efficiency adjustment reduction into commercial revenue. Practices should audit every payer contract for Medicare-linked fee schedule references and trigger renegotiation clauses before end of year. For specialties absorbing 10 to 20% cuts on specific codes, recovering even half that reduction through commercial renegotiation materially changes the practice's financial trajectory.

Service mix adjustment is more operationally complex. The distinction between facility-based and non-facility-based settings now carries an 11 to 17 percentage point reimbursement difference for oncology, which makes the financial case for community-based infusion centers urgent for hospital-employed oncologists evaluating their employment arrangements. High-procedure-volume ophthalmologists in ambulatory surgical centers should model the practice expense RVU differential before renewing facility contracts.

For all three specialties, the decision about facility affiliation deserves formal financial modeling, not deferred planning. CMS has signaled a durable preference for non-facility-based service delivery through both the PE RVU methodology change and the Ambulatory Specialty Model, described below. That preference will shape reimbursement policy through the next decade.

The Compounding Risk: How the Efficiency Adjustment Interacts With TEAM, ASM, and Two-Sided Risk Models

The efficiency adjustment does not operate in isolation. Two other programs finalized in or alongside the 2026 rule introduce downside risk that compounds for the same specialties already absorbing wRVU reductions.

The Transforming Episode Accountability Model (TEAM), mandatory beginning January 2026 for approximately 741 acute care hospitals across 188 markets, creates financial accountability for five surgical episodes through 30 days post-discharge. Specialists performing procedures covered by TEAM episodes, including spinal fusion and lower extremity joint replacement, are now operating inside hospital financial risk structures while simultaneously receiving reduced work RVU valuations on those same procedures.

The Ambulatory Specialty Model (ASM), finalized in the 2026 rule, introduces mandatory two-sided risk for specialists treating chronic conditions in outpatient settings. The performance period begins January 1, 2027, with payment adjustment years running from 2029 through 2033. ASM payment adjustments can reach negative 9 to 12% depending on performance year. A specialist already facing a 10 to 20% net reimbursement reduction from the efficiency adjustment and facility PE changes who then receives a negative ASM adjustment in 2029 is looking at a 20 to 30% revenue contraction from CMS policy alone.

The efficiency adjustment's triennial reset and the ASM payment adjustment window are synchronized: both hit in the 2029 to 2033 period. Practices that treat the 2026 cuts as a one-time event will face the compounded version without preparation. The planning window to avoid that outcome is now, not when the 2029 performance data comes back.